Kai-Henrik Peiffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kai-Henrik Peiffer has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Jonel Trebicka
Department of Medicine B University Hospital Münster Münster Germany
12 shared publications Stefan Zeuzem
Goethe University Frankfurt, Medical Clinic 1, University Hospital, Frankfurt am Main, Germany
12 shared publications- Eberhard Hildt
Research Group, Paul-Ehrlich-Institute, 63225 Langen, Germany
8 shared publications - Michael Praktiknjo
Department of Medicine B University Hospital Münster Münster Germany
7 shared publications - Wenyu Gu
Institute of Environmental Engineering, ENAC, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015, Lausanne, Switzerland
7 shared publications Christoph Sarrazin
Department of Gastroenterology and Hepatology University Hospital Frankfurt Frankfurt Germany
6 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1) , 460
HBV re-activation is associated with increased mortality and dysregulation of oxidative and polyamine metabolism in pre-acute-on-chronic liver failure
Background/Aims: Acute-on-chronic liver failure (ACLF) is one of the deadliest complications of chronic liver disease yet treatment options are sparse. In Asia, HBV-reactivation (HBVr) is one of the most common triggers. Recently, HBV-associated ACLF was associated with distinct changes in the metabolome. Here, metabolic impacts of HBVr were analysed in-depth in non-ACLF, pre-ACLF and ACLF. Methods: Clinical and metabolic data of 1024 Chinese patients (CATCH-LIFE studies) with chronic HBV mono-infection were analyzed. ACLF was diagnosed according to COSSH criteria. Metabolites in plasma were quantified using LC-MS, compared to non-ACLF and subjected to enrichment and pathway analyses using the database SMPDB via MetaboAnalyst v6. Results: In 1024 patients (611: non-ACLF, 72: pre-ACLF, 341: ACLF), HBVr was present in 20.2% (ACLF) or 33.3% (pre-ACLF) of patients. HBVr increased 28-day mortality in pre-ACLF patients (2.1% in HBVnr vs. 25% in HBVr). Energy metabolism generating reactive oxygen species (ROS) was highly induced in the absence of ROS-detoxifying pathways in pre-ACLF. Urea cycle, thus nitric oxide (NO) build-up, the polyamine metabolism and related pathways were highly increased in both HBVr pre-ACLF and ACLF, shifting pre-ACLF close to mature ACLF. Specific metabolites could be identified as putative markers and key-regulators herein. Conclusion: HBV reactivation induces inflammation, hepatic injury and mortality especially in pre-ACLF patients. Metabolic disruption in the ROS/NO/polyamine axis favors stress and hinders liver regeneration. Findings help identifying and alleviating HBVr-driven progression towards ACLF via pharmacological or biopharmaceutical intervention. Trial registration: Analyses were based on the CATCH-LIFE studies. The CATCH-LIFE studies were registered at Clinical.trials.gov (Clinical Trial Number: NCT02457637, first registered 2015-01-31 and NCT03641872, first registered 2018-08-14).
- 24 August 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1) , 460
Open AccessHBV re-activation is associated with increased mortality and dysregulation of oxidative and polyamine metabolism in pre-acute-on-chronic liver failure
Background/Aims: Acute-on-chronic liver failure (ACLF) is one of the deadliest complications of chronic liver disease yet treatment options are sparse. In Asia, HBV-reactivation (HBVr) is one of the most common triggers. Recently, HBV-associated ACLF was associated with distinct changes in the metabolome. Here, metabolic impacts of HBVr were analysed in-depth in non-ACLF, pre-ACLF and ACLF. Methods: Clinical and metabolic data of 1024 Chinese patients (CATCH-LIFE studies) with chronic HBV mono-infection were analyzed. ACLF was diagnosed according to COSSH criteria. Metabolites in plasma were quantified using LC-MS, compared to non-ACLF and subjected to enrichment and pathway analyses using the database SMPDB via MetaboAnalyst v6. Results: In 1024 patients (611: non-ACLF, 72: pre-ACLF, 341: ACLF), HBVr was present in 20.2% (ACLF) or 33.3% (pre-ACLF) of patients. HBVr increased 28-day mortality in pre-ACLF patients (2.1% in HBVnr vs. 25% in HBVr). Energy metabolism generating reactive oxygen species (ROS) was highly induced in the absence of ROS-detoxifying pathways in pre-ACLF. Urea cycle, thus nitric oxide (NO) build-up, the polyamine metabolism and related pathways were highly increased in both HBVr pre-ACLF and ACLF, shifting pre-ACLF close to mature ACLF. Specific metabolites could be identified as putative markers and key-regulators herein. Conclusion: HBV reactivation induces inflammation, hepatic injury and mortality especially in pre-ACLF patients. Metabolic disruption in the ROS/NO/polyamine axis favors stress and hinders liver regeneration. Findings help identifying and alleviating HBVr-driven progression towards ACLF via pharmacological or biopharmaceutical intervention. Trial registration: Analyses were based on the CATCH-LIFE studies. The CATCH-LIFE studies were registered at Clinical.trials.gov (Clinical Trial Number: NCT02457637, first registered 2015-01-31 and NCT03641872, first registered 2018-08-14).
- Open Access
- 6 July 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (9) , e01071
Short-Term Mortality is Reduced and Low-Grade Acute-on-Chronic Liver Failure Reversed by Transjugular Intrahepatic Portosystemic Shunt in Patients With Fluid Overload: A Case-Control Study
INTRODUCTION: Portal hypertension characterizes decompensated cirrhosis and its complications. It may trigger acute-on-chronic liver failure (ACLF), which carries a high mortality. Transjugular intrahepatic portosystemic shunt (TIPS) is the most efficient therapy for most portal hypertension-related complications including fluid overload (FO) defined as refractory or recurrent ascites, hepatorenal syndrome, and/or hydrothorax. However, TIPS for FO in ACLF is questioned. METHODS: In this case-control study, patients from the prospective cohorts CANONIC (n = 1,324) and German TIPS-Registry (n = 724) were screened for cases of FO and matched 1:1 by sex, age, Model for End-Stage Liver Disease (MELD) score, and presence and grade of ACLF. Clinical outcomes, ACLF status, and mortality were assessed. RESULTS: The total population was 118 patients with ACLF of whom 59 received TIPS and 59 did not. The main indication for TIPS was hepatorenal syndrome (61.0%). Patients with ACLF who did not receive TIPS had a higher 28-day cumulative mortality rate (22.0% vs 5.1%, P = 0.009). At 28 days, TIPS insertion in ACLF was associated with a 78% mortality reduction (hazard ratio 0.22 [0.06–0.77]). It further led to improvement of hepatic encephalopathy and the MELD score. In addition, ACLF resolution occurred in 61% of TIPS patients with ACLF. The presence of coagulation and circulatory organ failures, and increased bilirubin, INR, MELD score, and CLIF-C OF were associated with 28-day mortality. The survival benefit of TIPS was no longer observed after 90 days. DISCUSSION: TIPS decreased the 28-day mortality of patients with FO and ACLF. Thus, TIPS should be regarded as a bridging strategy—ideally for liver transplantation.
- 6 July 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (9) , e01071
Open AccessShort-Term Mortality is Reduced and Low-Grade Acute-on-Chronic Liver Failure Reversed by Transjugular Intrahepatic Portosystemic Shunt in Patients With Fluid Overload: A Case-Control Study
INTRODUCTION: Portal hypertension characterizes decompensated cirrhosis and its complications. It may trigger acute-on-chronic liver failure (ACLF), which carries a high mortality. Transjugular intrahepatic portosystemic shunt (TIPS) is the most efficient therapy for most portal hypertension-related complications including fluid overload (FO) defined as refractory or recurrent ascites, hepatorenal syndrome, and/or hydrothorax. However, TIPS for FO in ACLF is questioned. METHODS: In this case-control study, patients from the prospective cohorts CANONIC (n = 1,324) and German TIPS-Registry (n = 724) were screened for cases of FO and matched 1:1 by sex, age, Model for End-Stage Liver Disease (MELD) score, and presence and grade of ACLF. Clinical outcomes, ACLF status, and mortality were assessed. RESULTS: The total population was 118 patients with ACLF of whom 59 received TIPS and 59 did not. The main indication for TIPS was hepatorenal syndrome (61.0%). Patients with ACLF who did not receive TIPS had a higher 28-day cumulative mortality rate (22.0% vs 5.1%, P = 0.009). At 28 days, TIPS insertion in ACLF was associated with a 78% mortality reduction (hazard ratio 0.22 [0.06–0.77]). It further led to improvement of hepatic encephalopathy and the MELD score. In addition, ACLF resolution occurred in 61% of TIPS patients with ACLF. The presence of coagulation and circulatory organ failures, and increased bilirubin, INR, MELD score, and CLIF-C OF were associated with 28-day mortality. The survival benefit of TIPS was no longer observed after 90 days. DISCUSSION: TIPS decreased the 28-day mortality of patients with FO and ACLF. Thus, TIPS should be regarded as a bridging strategy—ideally for liver transplantation.
- Open Access
- 23 June 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (6) , e70602
Conversion to LCP Tacrolimus Mitigates Calcineurin‐Induced Nephrotoxicity in Patients After Liver Transplantation
Background: Calcineurin inhibitor (CNI)‐induced nephrotoxicity after liver transplantation (LT) is linked to increased morbidity and mortality. LCPT offers a particular extended‐release formulation, potentially improving the concentration‐dose (C/D) ratio and renal outcomes. This study investigated the impact of switching from standard‐release Tacrolimus (SR‐Tac) to LCPT on C/D ratio and renal function. Methods: 170 adult LT recipients (August 2008–March 2020) treated with tacrolimus for at least two years were included. In this single‐center, retrospective analysis, 63 patients converted to LCPT, while 107 patients continued on SR‐Tac. Clinical data were collected every three months over 24 months. Results: At baseline, median C/D ratios were similar between groups ( p = 0.553), the LCPT group showed significantly higher C/D ratios compared to SR‐Tac during both the first ( p = 0.003) and second year ( p = 0.004). While LCPT‐treated patients showed an increased mean estimated glomerular filtration rate (eGFR), the SR‐Tac group exhibited a progressive decline at each follow‐up (mean decline: −5.4 mL/min/1.73m 2 at 24 months, p p p = 0.043), and baseline eGFR ( p = 0.038) as significant predictors of eGFR change. Conclusion: Conversion to LCPT may improve renal function in LT recipients over two years, suggesting potential long‐term nephroprotection without compromising graft function.
- 23 June 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (6) , e70602
Open AccessConversion to LCP Tacrolimus Mitigates Calcineurin‐Induced Nephrotoxicity in Patients After Liver Transplantation
Background: Calcineurin inhibitor (CNI)‐induced nephrotoxicity after liver transplantation (LT) is linked to increased morbidity and mortality. LCPT offers a particular extended‐release formulation, potentially improving the concentration‐dose (C/D) ratio and renal outcomes. This study investigated the impact of switching from standard‐release Tacrolimus (SR‐Tac) to LCPT on C/D ratio and renal function. Methods: 170 adult LT recipients (August 2008–March 2020) treated with tacrolimus for at least two years were included. In this single‐center, retrospective analysis, 63 patients converted to LCPT, while 107 patients continued on SR‐Tac. Clinical data were collected every three months over 24 months. Results: At baseline, median C/D ratios were similar between groups ( p = 0.553), the LCPT group showed significantly higher C/D ratios compared to SR‐Tac during both the first ( p = 0.003) and second year ( p = 0.004). While LCPT‐treated patients showed an increased mean estimated glomerular filtration rate (eGFR), the SR‐Tac group exhibited a progressive decline at each follow‐up (mean decline: −5.4 mL/min/1.73m 2 at 24 months, p p p = 0.043), and baseline eGFR ( p = 0.038) as significant predictors of eGFR change. Conclusion: Conversion to LCPT may improve renal function in LT recipients over two years, suggesting potential long‐term nephroprotection without compromising graft function.
- Open Access
- 30 May 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (3) , 442-449
First-in-human European experience with novel 22-G end-cutting fine-needle biopsy system: a prospective observational pilot study
Background/Aims: Endoscopic ultrasound (EUS)-guided biopsy remains a cornerstone for diagnosing and staging gastrointestinal diseases. Various systems are available, with needle designs for fine-needle aspiration and fine-needle biopsy (FNB) and gauges from 25-G to 19-G. We aimed to report the first European human experience with a novel 22-G end-cutting FNB system (EchoTip ClearCore; Cook Medical).Methods: This prospective observational study was conducted at our tertiary endoscopy center between November and December 2024. All patients undergoing EUS-guided puncture with the 22-G EchoTip ClearCore needle were included. User and patient experience were assessed using questionnaires. Clinical data were obtained from electronic hospital records.Results: Ten patients underwent 15 EUS-guided biopsies. The median patient age was 57 (range, 18–77) years, and 60% were male. Indications included liver biopsy for elevated liver enzymes or post-transplantation assessment (67%), evaluation of pancreatic lesions (20%), and sampling of pathological lymph nodes (13%). The technical success rate was 100%. Specimen quality was sufficient for diagnosis in 93% of cases. Operators rated the needle highly for EUS visibility (8.8/10), maneuverability and stability (7.9/10), and ease of tissue penetration (8.3/10). Overall patient satisfaction was high (5/5); no complications occurred.Conclusions: The 22-G EchoTip ClearCore needle is safe and effective, demonstrating excellent technical and clinical outcomes.
- 30 May 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (3) , 442-449
Open AccessFirst-in-human European experience with novel 22-G end-cutting fine-needle biopsy system: a prospective observational pilot study
Background/Aims: Endoscopic ultrasound (EUS)-guided biopsy remains a cornerstone for diagnosing and staging gastrointestinal diseases. Various systems are available, with needle designs for fine-needle aspiration and fine-needle biopsy (FNB) and gauges from 25-G to 19-G. We aimed to report the first European human experience with a novel 22-G end-cutting FNB system (EchoTip ClearCore; Cook Medical).Methods: This prospective observational study was conducted at our tertiary endoscopy center between November and December 2024. All patients undergoing EUS-guided puncture with the 22-G EchoTip ClearCore needle were included. User and patient experience were assessed using questionnaires. Clinical data were obtained from electronic hospital records.Results: Ten patients underwent 15 EUS-guided biopsies. The median patient age was 57 (range, 18–77) years, and 60% were male. Indications included liver biopsy for elevated liver enzymes or post-transplantation assessment (67%), evaluation of pancreatic lesions (20%), and sampling of pathological lymph nodes (13%). The technical success rate was 100%. Specimen quality was sufficient for diagnosis in 93% of cases. Operators rated the needle highly for EUS visibility (8.8/10), maneuverability and stability (7.9/10), and ease of tissue penetration (8.3/10). Overall patient satisfaction was high (5/5); no complications occurred.Conclusions: The 22-G EchoTip ClearCore needle is safe and effective, demonstrating excellent technical and clinical outcomes.
- Open Access
- 9 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101627
Higher prevalence of cytomegalovirus and Epstein–Barr virus in acute-on-chronic liver failure
- 9 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101627
Open AccessHigher prevalence of cytomegalovirus and Epstein–Barr virus in acute-on-chronic liver failure
- Open Access
- 1 June 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (3) , 60
The Underestimated Threat—Mycobacterium Genavense Infection: A Case Report
Background/Objectives: Nontuberculous mycobacteria (NTM) represent a heterogeneous group of pathogens with increasing global prevalence and significant geographical variation in species distribution. NTM infections, often affecting immunocompromised individuals, are difficult to diagnose due to nonspecific clinical presentations and laboratory findings. This case study presents a rare extrapulmonary NTM infection in a 73-year-old man, initially misdiagnosed as sarcoidosis, highlighting the diagnostic and therapeutic challenges posed by such infections. Methods: The patient, a pigeon fancier, presented with recurrent fever and pancytopenia. Extensive diagnostics included blood cultures, bone marrow aspiration, and histopathology. Initial cultures and serological tests remained negative. Results: Bone marrow aspiration revealed epithelioid granulomas, initially leading to the provisional diagnosis of sarcoidosis. However, after six weeks, M. genavense was isolated from mycobacterial blood cultures from bone marrow aspirant. Antimicrobial therapy with azithromycin, rifampicin, and ethambutol was initiated. Following the initiation of appropriate antimycobacterial therapy, the patient developed immune reconstitution inflammatory syndrome (IRIS), which was managed with supportive care. The patient’s condition improved, and no further febrile episodes occurred post-treatment, marking the successful conclusion of NTM therapy. Conclusions: This case underscores the diagnostic complexity of extrapulmonary NTM infections, particularly in immunocompromised patients. Misdiagnosis can delay appropriate treatment. M. genavense, though rare, should be considered in patients with a fever of unknown origin, especially with a background of immunosuppression. Prompt mycobacterial testing and tailored antibiotic therapy are crucial to improving outcomes in NTM infections.
- 1 June 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (3) , 60
Open AccessThe Underestimated Threat—Mycobacterium Genavense Infection: A Case Report
Background/Objectives: Nontuberculous mycobacteria (NTM) represent a heterogeneous group of pathogens with increasing global prevalence and significant geographical variation in species distribution. NTM infections, often affecting immunocompromised individuals, are difficult to diagnose due to nonspecific clinical presentations and laboratory findings. This case study presents a rare extrapulmonary NTM infection in a 73-year-old man, initially misdiagnosed as sarcoidosis, highlighting the diagnostic and therapeutic challenges posed by such infections. Methods: The patient, a pigeon fancier, presented with recurrent fever and pancytopenia. Extensive diagnostics included blood cultures, bone marrow aspiration, and histopathology. Initial cultures and serological tests remained negative. Results: Bone marrow aspiration revealed epithelioid granulomas, initially leading to the provisional diagnosis of sarcoidosis. However, after six weeks, M. genavense was isolated from mycobacterial blood cultures from bone marrow aspirant. Antimicrobial therapy with azithromycin, rifampicin, and ethambutol was initiated. Following the initiation of appropriate antimycobacterial therapy, the patient developed immune reconstitution inflammatory syndrome (IRIS), which was managed with supportive care. The patient’s condition improved, and no further febrile episodes occurred post-treatment, marking the successful conclusion of NTM therapy. Conclusions: This case underscores the diagnostic complexity of extrapulmonary NTM infections, particularly in immunocompromised patients. Misdiagnosis can delay appropriate treatment. M. genavense, though rare, should be considered in patients with a fever of unknown origin, especially with a background of immunosuppression. Prompt mycobacterial testing and tailored antibiotic therapy are crucial to improving outcomes in NTM infections.
- 3 August 2024
- Published by Springer Nature
- p. 1635-1645
Anaphylaxie – Diagnostik und Therapie unter intensivmedizinischen Gesichtspunkten
- 3 August 2024
- Published by Springer Nature
- p. 1635-1645
Anaphylaxie – Diagnostik und Therapie unter intensivmedizinischen Gesichtspunkten
- Open Access
- 1 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1438
Risk Factors for Infectious Complications following Endoscopic Retrograde Cholangiopancreatography in Liver Transplant Patients: A Single-Center Study
Background: Liver transplant recipients often require endoscopic retrograde cholangiopancreatography (ERCP) for biliary complications, which can lead to infections. This retrospective single-center study aimed to identify risk factors for infectious complications following ERCP in liver transplant patients. Methods: A retrospective analysis was conducted on 285 elective ERCP interventions performed in 88 liver transplant patients at a tertiary care center. The primary endpoint was the occurrence of an infection following ERCP. Univariable and multivariable regression analyses, Cox regression, and log-rank tests were employed to assess the influence of various factors on the incidence of infectious complications. Results: Among the 285 ERCP interventions, isolated anastomotic stenosis was found in 175 cases, ischemic type biliary lesion (ITBL) in 103 cases, and choledocholithiasis in seven cases. Bile duct interventions were performed in 96.9% of all ERCPs. Infections after ERCP occurred in 46 cases (16.1%). Independent risk factors for infection included male sex (OR 24.19), prednisolone therapy (OR 4.5), ITBL (OR 4.51), sphincterotomy (OR 2.44), cholangioscopy (OR 3.22), dilatation therapy of the bile ducts (OR 9.48), and delayed prophylactic antibiotic therapy (>1 h after ERCP) (OR 2.93). Additionally, infections following previous ERCP interventions were associated with an increased incidence of infections following future ERCP interventions (p < 0.0001). Conclusion: In liver transplant patients undergoing ERCP, male sex, prednisolone therapy, and complex bile duct interventions independently raised infection risks. Delayed antibiotic treatment further increased this risk. Patients with ITBL were notably susceptible due to incomplete drainage. Additionally, a history of post-ERCP infections signaled higher future risks, necessitating close monitoring and timely antibiotic prophylaxis.
- 1 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1438
Open AccessRisk Factors for Infectious Complications following Endoscopic Retrograde Cholangiopancreatography in Liver Transplant Patients: A Single-Center Study
Background: Liver transplant recipients often require endoscopic retrograde cholangiopancreatography (ERCP) for biliary complications, which can lead to infections. This retrospective single-center study aimed to identify risk factors for infectious complications following ERCP in liver transplant patients. Methods: A retrospective analysis was conducted on 285 elective ERCP interventions performed in 88 liver transplant patients at a tertiary care center. The primary endpoint was the occurrence of an infection following ERCP. Univariable and multivariable regression analyses, Cox regression, and log-rank tests were employed to assess the influence of various factors on the incidence of infectious complications. Results: Among the 285 ERCP interventions, isolated anastomotic stenosis was found in 175 cases, ischemic type biliary lesion (ITBL) in 103 cases, and choledocholithiasis in seven cases. Bile duct interventions were performed in 96.9% of all ERCPs. Infections after ERCP occurred in 46 cases (16.1%). Independent risk factors for infection included male sex (OR 24.19), prednisolone therapy (OR 4.5), ITBL (OR 4.51), sphincterotomy (OR 2.44), cholangioscopy (OR 3.22), dilatation therapy of the bile ducts (OR 9.48), and delayed prophylactic antibiotic therapy (>1 h after ERCP) (OR 2.93). Additionally, infections following previous ERCP interventions were associated with an increased incidence of infections following future ERCP interventions (p < 0.0001). Conclusion: In liver transplant patients undergoing ERCP, male sex, prednisolone therapy, and complex bile duct interventions independently raised infection risks. Delayed antibiotic treatment further increased this risk. Patients with ITBL were notably susceptible due to incomplete drainage. Additionally, a history of post-ERCP infections signaled higher future risks, necessitating close monitoring and timely antibiotic prophylaxis.
- Open Access
- 15 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Use and outcome of TIPS in hospitalized patients in Germany: A Nationwide study (2007–2018)
Background: The number of complications in patients admitted for cirrhosis has increased over time. Portal hypertension is the driver of many complications of cirrhosis. TIPS placement is the most effective treatment of portal hypertension. The aim of this study was to analyze the use and impact of TIPS placement in the last decade in a nationwide study in Germany. Methods: We analyzed 14,598 admissions of patients for TIPS insertions in Germany from 2007 to 2018 using the DRG system, 12,877 out of 2,000,765 total admissions of patients with cirrhosis. All diagnoses and procedures were coded according to ICD-10-CM and OPS codes. The data were analyzed, focusing on the number of admissions and in-hospital mortality. Results: The number of TIPS placements increased over the last decade. In-hospital mortality of cirrhotic patients with TIPS decreased when it was placed for severe bleeding (15.2% [TIPS] vs. 19.5% [endoscopy treatment]), ascites (8.7% [TIPS] vs. 14.4% [paracentesis]), and hepatorenal syndrome (HRS) (17.1% [TIPS] vs. 43.3% [no-TIPS]). In the case of bleeding, TIPS significantly decreased in-hospital mortality and also in ascites and HRS. During hospitalization, 22.6% admissions of patients with TIPS insertion showed HE. However, in-hospital mortality in patients admitted with HE grades 1 or 2 and TIPS was lower than in patients without TIPS. In the logistic regression, a higher HE grade(3 and 4), infection, and circulatory disease were found to be independently associated with in-hospital mortality in patients with TIPS insertion. Conclusion: Our nationwide study demonstrates that TIPS insertion is increasingly used in Germany. TIPS improves outcomes, especially in patients with ascites and HRS, regardless of lower HE grades, while higher HE grades, infection, and circulatory diseases seem to be associated with risk of in-hospital mortality. Export
- 15 September 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Open AccessUse and outcome of TIPS in hospitalized patients in Germany: A Nationwide study (2007–2018)
Background: The number of complications in patients admitted for cirrhosis has increased over time. Portal hypertension is the driver of many complications of cirrhosis. TIPS placement is the most effective treatment of portal hypertension. The aim of this study was to analyze the use and impact of TIPS placement in the last decade in a nationwide study in Germany. Methods: We analyzed 14,598 admissions of patients for TIPS insertions in Germany from 2007 to 2018 using the DRG system, 12,877 out of 2,000,765 total admissions of patients with cirrhosis. All diagnoses and procedures were coded according to ICD-10-CM and OPS codes. The data were analyzed, focusing on the number of admissions and in-hospital mortality. Results: The number of TIPS placements increased over the last decade. In-hospital mortality of cirrhotic patients with TIPS decreased when it was placed for severe bleeding (15.2% [TIPS] vs. 19.5% [endoscopy treatment]), ascites (8.7% [TIPS] vs. 14.4% [paracentesis]), and hepatorenal syndrome (HRS) (17.1% [TIPS] vs. 43.3% [no-TIPS]). In the case of bleeding, TIPS significantly decreased in-hospital mortality and also in ascites and HRS. During hospitalization, 22.6% admissions of patients with TIPS insertion showed HE. However, in-hospital mortality in patients admitted with HE grades 1 or 2 and TIPS was lower than in patients without TIPS. In the logistic regression, a higher HE grade(3 and 4), infection, and circulatory disease were found to be independently associated with in-hospital mortality in patients with TIPS insertion. Conclusion: Our nationwide study demonstrates that TIPS insertion is increasingly used in Germany. TIPS improves outcomes, especially in patients with ascites and HRS, regardless of lower HE grades, while higher HE grades, infection, and circulatory diseases seem to be associated with risk of in-hospital mortality. Export
- 29 August 2023
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 44 (S 01) , S46
Ultrasound-defined sarcopenia independently predicts acute decompensation in advanced chronic liver disease
Einleitung und Fragestellung It has been shown that in patients with liver cirrhosis, sarcopenia may be a predictor of a less favourable outcome. However, the most common methods for diagnosing sarcopenia are sometimes expensive or too complex to use in patients for whom transjugular intrahepatic portosystemic shunt (TIPS) is an option. Therefore, in this study, we propose the muscle thickness of quadriceps femoris muscle measured by ultrasound to identify patients with sarcopenia and we investigated whether acute decompensation (AD) and all-cause death was more frequent in them. Material und Methodik Sixty-three patients with chronic liver disease, who did not receive a TIPS because of contraindications or insufficient indication, were analysed in this monocentric study for the occurrence of complications such as hepatic encephalopathy, ascites, haemorrhage, or liver-related death. Ergebnisse We compared three different heights of the muscle in terms of suitability as a predictor and found the upper third of the muscle, measured without applying pressure with the transducer, to be the most appropriate. Cut-off values of ultrasound-defined muscle thickness standardized per height for identifying sarcopenia were determined. The groups thus defined differed significantly, with patients with sarcopenia showing an increase in mortality and in the incidence of ADs. Zusammenfassung Sarcopenia classification based on ultrasound measurements is shown to be an independent predictor of AD occurrence within one year. This pilot study is the first to suggest that screening for sarcopenia by ultrasonography may be useful for risk assessment in patients being evaluated for TIPS. Article published online: 29 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 29 August 2023
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 44 (S 01) , S46
Ultrasound-defined sarcopenia independently predicts acute decompensation in advanced chronic liver disease
Einleitung und Fragestellung It has been shown that in patients with liver cirrhosis, sarcopenia may be a predictor of a less favourable outcome. However, the most common methods for diagnosing sarcopenia are sometimes expensive or too complex to use in patients for whom transjugular intrahepatic portosystemic shunt (TIPS) is an option. Therefore, in this study, we propose the muscle thickness of quadriceps femoris muscle measured by ultrasound to identify patients with sarcopenia and we investigated whether acute decompensation (AD) and all-cause death was more frequent in them. Material und Methodik Sixty-three patients with chronic liver disease, who did not receive a TIPS because of contraindications or insufficient indication, were analysed in this monocentric study for the occurrence of complications such as hepatic encephalopathy, ascites, haemorrhage, or liver-related death. Ergebnisse We compared three different heights of the muscle in terms of suitability as a predictor and found the upper third of the muscle, measured without applying pressure with the transducer, to be the most appropriate. Cut-off values of ultrasound-defined muscle thickness standardized per height for identifying sarcopenia were determined. The groups thus defined differed significantly, with patients with sarcopenia showing an increase in mortality and in the incidence of ADs. Zusammenfassung Sarcopenia classification based on ultrasound measurements is shown to be an independent predictor of AD occurrence within one year. This pilot study is the first to suggest that screening for sarcopenia by ultrasonography may be useful for risk assessment in patients being evaluated for TIPS. Article published online: 29 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany